$151 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QGEN | QIAGEN NV | $4,424,000 | +7.2% | 160,000 | 0.0% | 2.92% | +28.3% | |
| HOLX | HOLOGIC INC | $1,857,000 | -1.1% | 48,000 | 0.0% | 1.23% | +18.3% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $1,503,000 | -8.1% | 102,200 | 0.0% | 0.99% | +10.0% | |
| VCEL | VERICEL CORP | $857,000 | -4.8% | 332,157 | 0.0% | 0.57% | +13.9% | |
| NVAX | NOVAVAX INCput | $839,000 | +18.7% | 100,000 | 0.0% | 0.55% | +42.1% | |
| NVAX | NOVAVAX INCcall | $839,000 | +18.7% | 100,000 | 0.0% | 0.55% | +42.1% | |
| FLML | FLAMEL TECHNOLOGIES SAsponsored adr | $693,000 | -25.2% | 56,788 | 0.0% | 0.46% | -10.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.